Fundz

AeroRx Therapeutics raises $21 million in Series A financing led by Avalon BioVentures to advance AERO-007 for COPD.

PRIVATEOct 07, 2025

Amount Raised

$21 Million

Round Type

Series A

San DiegoBiotechnologyHealth Care

Investors

Avalon BioVenturesCorrelation VenturesAlexandria Venture Investments

Description

AeroRx Therapeutics announced a $21 million Series A financing led by Avalon BioVentures, with participation from Correlation Ventures and Alexandria Venture Investments. The funds will support late-stage clinical development of AERO-007, a potential first-line treatment for COPD. Data from a Phase 2a study showed AERO-007 was well tolerated and provided sustained bronchodilation. This financing positions AeroRx to advance toward a Phase 2b dose-optimization study.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as AeroRx Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • BeyondSpring raised $2M (Funding Round) on November 21, 2025.
  • Ultrahuman raised $11M (Debt Financing) on November 21, 2025.
  • ClearPoint Neuro raised $18M on November 20, 2025.
  • Sophrosyne Technologies raised $2M (Seed) on November 20, 2025.
  • Voio raised $8.6M (Seed) on November 20, 2025.
  • Emm raised $9M (Seed) on November 19, 2025.

Who to call at AeroRx Therapeutics, and when

A new round usually means AeroRx Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AeroRx Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AeroRx Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AeroRx Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AeroRx Therapeutics

Location

San Diego, California, United States

About

AeroRx Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary nebulized combination therapies for chronic respiratory diseases. Their lead candidate, inhaled AERO-007, is a novel nebulized LABA/LAMA treatment for chronic obstructive pulmonary disease (COPD). The company aims to improve patient adherence and outcomes by providing an alternative to traditional inhalers.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AeroRx Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for AeroRx Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

AeroRx Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.